PENTAX Medical, Hitachi Medical Systems Europe Strategic Partnership in UK
News Apr 15, 2014
PENTAX Medical and Hitachi Medical Systems have a successful strategic partnership in the area of endoscopic ultrasound (EUS), combining the PENTAX Medical optical/endoscopic expertise with Hitachi Medical Systems core ultrasound expertise.
A series of state-of-the-art ultrasound endoscopes were jointly developed within the framework of this collaboration; the latest one being the PENTAX EG-3270UK which takes user and patient comfort to a new level due to its exceptional slim size. PENTAX Medical and Hitachi Medical Systems have now renewed and reinforced this partnership for maximum customer benefit. Hitachi Medical Systems is the sole partner of PENTAX Medical to sell and service PENTAX ultrasound endoscopes in the United Kingdom. With its highly qualified technical and medical EUS specialists Hitachi Medical Systems offers an unprecedented level of support to clinicians.
The added value of this strategic collaboration for the clinician is exceptionally sharp and clear diagnostic images that enable them to reliably identify even very small lesions.
Further important clinical benefits such as Contrast Harmonic Imaging, Imaging Fusion like Picture-in-Picture, EUS-Fine Needle Aspiration and Hitachi Real-Time Elastography (HI-RTE) add to the superior diagnostic functionality. Highly experienced application specialists of Hitachi Medical Systems are ready to support the clinical user as required.
David Moore, Managing Director, PENTAX Medical UK Ltd, said: “I am convinced that the renewed strategic collaboration with Hitachi Medical Systems as our sole sales and technical service partner in EUS will strongly support our ambitious growth targets in endoscopic Ultrasound and in our core business.”
Stephen Brookes, Managing Director, Hitachi Medical Systems UK Ltd, said: “The bundling of expert knowledge and skills enabled by this strategic partnership adds exceptional value to the clinicians by giving them the highest achievable diagnostic security – from expert to expert.”
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE